Skip to main content
. Author manuscript; available in PMC: 2014 May 7.
Published in final edited form as: Cell Metab. 2013 May 7;17(5):695–708. doi: 10.1016/j.cmet.2013.04.001

Figure 2.

Figure 2

Neutrophil-derived S100A8/A9 promotes leukocytosis via increased proliferation of BM progenitor cells.

(A) Plasma levels of S100A8/A9 in STZ-diabetic mice treated with SGLT2i. n=6.

(B) mRNA expression of S100a8, S100a9 and Hmgb1 in FACS isolated neutrophils. n=6, *P<0.05 vs. WT, ^P<0.05 vs. WT+STZ group.

(C) Total BM cells were isolated from WT mice and cultured in HG (25mM, 16hrs) and stimulated with S100A8/A9 complex. GMP proliferation was assessed by measuring EdU incorporation via flow cytometry. n=4 independent experiments, *P<0.05 vs. vehicle.

(D) Monocyte levels and (E) BM progenitor cells in WT mice in response to vehicle or S100A8/A9 complex (20μg/kg/mouse, i.v, twice daily, 3 days) *P<0.05 vs. vehicle.

(F-I) S100a9−/− BMT: (F) Experimental overview: WT mice were transplanted with BM from either WT or S100a9−/− mice and made diabetic with STZ. (G) Blood leukocyte levels after 4 weeks of diabetes. (H) Percentage of HSPCs, CMPs and GMPs in the BM and (I) percentage of HSPCs, CMPs and GMPs in the G2M phase of the cell cycle. D-I, n=5/group. *P<0.05 vs. all groups.

All values are means ± SEM.